A5029061749- Breast Cancer Treatment Studies
- Breast Lesions and Carcinomas
- HER2/EGFR in Cancer Research
- Cancer Genomics and Diagnostics
- Radiomics and Machine Learning in Medical Imaging
- Cancer Treatment and Pharmacology
- Cancer Immunotherapy and Biomarkers
- Molecular Biology Techniques and Applications
- Cancer Cells and Metastasis
- Global Cancer Incidence and Screening
- Gene expression and cancer classification
- AI in cancer detection
- Medical Imaging Techniques and Applications
- Inflammatory Biomarkers in Disease Prognosis
- Cell Image Analysis Techniques
- Lung Cancer Diagnosis and Treatment
- Salivary Gland Disorders and Functions
- Advanced X-ray and CT Imaging
- Salivary Gland Tumors Diagnosis and Treatment
- Colorectal Cancer Screening and Detection
- Esophageal Cancer Research and Treatment
- Otolaryngology and Infectious Diseases
- Radiation Dose and Imaging
- Cancer Risks and Factors
- Advanced Breast Cancer Therapies
Oncode Institute
2017-2025
The Netherlands Cancer Institute
2017-2025
Dutch Cancer Society
2022
Amsterdam University Medical Centers
2019-2022
Amsterdam UMC Location Vrije Universiteit Amsterdam
2015
BackgroundPrevious studies have independently validated the prognostic relevance of residual cancer burden (RCB) after neoadjuvant chemotherapy. We used results from several independent cohorts in a pooled patient-level analysis to evaluate relationship RCB with long-term prognosis across different phenotypic subtypes breast cancer, assess generalisability broad range practice settings.MethodsIn this analysis, 12 institutes and trials Europe USA were identified by personal communications...
Abstract Tumor-infiltrating lymphocytes (TILs) have been associated with outcomes in HER2-positive breast cancer patients treated neoadjuvant chemotherapy and trastuzumab. However, it remains unclear if TILs could be a prognostic and/or predictive biomarker the context of dual HER2-targeting treatment. In this study, we evaluated association between pathological response (pCR) invasive-disease free survival (IDFS) 389 stage II-III HER2 positive who received anthracycline-containing or...
Pre-analytical factors, such as fixation time, influence morphology of diagnostic and predictive immunohistochemical staining, which are increasingly used in the evaluation lung cancer. Our aim was to investigate if variations time outcome staining From resections, specimen with tumor size bigger than 4 cm, 10 samples were obtained: 2 put through standard protocol, 5 delayed, 3 prolonged protocol. After paraffin embedding, tissue microarrays (TMAs) made. They stained 20 antibodies scored for...
Abstract The prognostic value of cytonuclear grade in ductal carcinoma situ (DCIS) is debated, partly due to high interobserver variability and the use multiple guidelines. aim this study was evaluate agreement grading DCIS between Dutch, British, American pathologists. Haematoxylin eosin‐stained slides 425 women with primary were independently reviewed by nine breast pathologists based Netherlands, UK, USA. Chance‐corrected kappa ( κ ma ) for association calculated on a generalised linear...
When locally advanced breast cancer is treated with neoadjuvant chemotherapy, the recurrence risk significantly higher if no complete pathologic response achieved. Identification of underlying resistance mechanisms essential to select treatments maximal efficacy and minimal toxicity. Here we employed gene expression profiles derived from 317 HER2-negative treatment-naïve biopsies patients who underwent deep whole exome, RNA-sequencing 22 matched pre- post-treatment tumors, treatment outcome...
Abstract Residual Cancer Burden (RCB) after neoadjuvant chemotherapy (NAC) is validated to predict event-free survival (EFS) in breast cancer but has not been studied for invasive lobular carcinoma (ILC). We patient-level data from a pooled cohort across 12 institutions. Associations between RCB index, class, and EFS were assessed ILC non-ILC with mixed effect Cox models multivariable analyses. Recursive partitioning was used an exploratory model stratify prognosis by components. Of 5106...
Abstract Purpose For optimal management of ductal carcinoma in situ (DCIS), reproducible histopathological assessment is essential to distinguish low-risk from high-risk DCIS. Therefore, we analyzed interrater reliability DCIS features and assessed their associations with subsequent ipsilateral invasive breast cancer (iIBC) risk. Methods Using a case-cohort design, was population-based, nationwide cohort 2767 women screen-detected diagnosed between 1993 2004, treated by breast-conserving...
Abstract Background: Recent studies have demonstrated independent validation of the prognostic relevance residual cancer burden (RCB) after neoadjuvant chemotherapy. However, a pooled subject-level analysis multiple cohorts is needed to determine estimates long-term prognosis for each class RCB in phenotypic subtype breast (BC) better inform on patient outcomes. Also, allows more detailed analyses generalizability meaning assessments broader experience practice settings. Method:...
Abstract Background Radiotherapy (RT) following breast-conserving surgery (BCS) for ductal carcinoma in situ (DCIS) reduces ipsilateral breast event rates clinical trials. This study assessed the impact of DCIS treatment on a 20-year risk (iDCIS) and invasive cancer (iIBC) population-based cohort. Methods The cohort comprised all women diagnosed with Netherlands during 1989–2004 follow-up until 2017. Cumulative incidence iDCIS iIBC BCS + RT were assessed. Associations estimated multivariable...
In breast cancer, pathologic complete response (pCR) to neoadjuvant systemic therapy (NST) is associated with favorable long-term outcome. Trastuzumab emtansine as additional adjuvant improves recurrence-free survival of patients HER2-positive cancer without pCR, but it uncertain whether all pCR need therapy. We evaluated the prognostic value residual disease after trastuzumab-based NST in using Residual Cancer Burden (RCB), Neoadjuvant Response Index (NRI), and Neo-Bioscore.We included...
Abstract Purpose To assess the effects of contemporary treatment ductal carcinoma in situ (DCIS) on risk developing an ipsilateral invasive breast cancer (iIBC) Dutch female population. Methods Clinical data was obtained from Netherlands Cancer Registry (NCR), a nationwide registry all primary malignancies integrated with PALGA, network and histo- cytopathology Netherlands, women treated for DCIS 2005 to 2015, resulting population-based cohort 14.419 women. Cumulative iIBC incidence assessed...
Gene expression (GE) profiling for breast cancer classification and prognostication has become increasingly used in clinical diagnostics. GE requires a reasonable tumor cell percentage high-quality RNA. As consequence, certain amount of samples drop out. If characteristics are different between included excluded from profiling, this can lead to bias. Therefore, we assessed whether patient differ tumors suitable or unsuitable generating profiles cancer. In consecutive cohort 738 patients who...
Abstract Background: Pathologic complete response (pCR) after neoadjuvant chemotherapy (NAC) in patients with breast cancer is associated improved survival. Further assessment of the extent residual disease, using pathological anatomic American Joint Committee on Cancer staging method (ypStage) or Residual Burden (RCB) method, have been shown to add prognostic information for disease. Neo-Bioscore, an alternate system classify NAC, includes clinical stage at diagnosis and biology defines...
Introduction: Candida infection of the salivary glands is extremely rare, and a parotid gland with tropicalis in an immunocompetent patient has, to best our knowledge, never been described before. Case presentation: A 76-year-old male known bilateral oncocytic lesions antibiotic suppression therapy for vascular endograft presented fever tender red mass left region. Although bacterial was suspected at first, cultures cyst aspirate yielded C. tropicalis. Once Gram stain indicated presence...
<p>Supplementary data to Steenbruggen TG, van Seijen M, Janssen LM, Ramshorst MS, Werkhoven E, Vrancken Peeters MJTDF, et al. Prognostic value of residual disease after neoadjuvant therapy in HER2-positive breast cancer evaluated by Residual Cancer Burden, Neoadjuvant Response Index & Neo-Bioscore. Table S1, S2, S3, S4, Text and legend Figure S1</p>
Figure S1 from Prognostic Value of Residual Disease after Neoadjuvant Therapy in HER2-Positive Breast Cancer Evaluated by Burden, Response Index, and Neo-Bioscore
Figure S1 from Prognostic Value of Residual Disease after Neoadjuvant Therapy in HER2-Positive Breast Cancer Evaluated by Burden, Response Index, and Neo-Bioscore
<p>Supplementary data to Steenbruggen TG, van Seijen M, Janssen LM, Ramshorst MS, Werkhoven E, Vrancken Peeters MJTDF, et al. Prognostic value of residual disease after neoadjuvant therapy in HER2-positive breast cancer evaluated by Residual Cancer Burden, Neoadjuvant Response Index & Neo-Bioscore. Table S1, S2, S3, S4, Text and legend Figure S1</p>
<div>AbstractPurpose:<p>In breast cancer, pathologic complete response (pCR) to neoadjuvant systemic therapy (NST) is associated with favorable long-term outcome. Trastuzumab emtansine as additional adjuvant improves recurrence-free survival of patients HER2-positive cancer without pCR, but it uncertain whether all pCR need therapy. We evaluated the prognostic value residual disease after trastuzumab-based NST in using Residual Cancer Burden (RCB), Neoadjuvant Response Index...